Avadel Pharmaceuticals PLC Sponsored ADR Aktie News

Alkermes said on Wednesday it has sweetened its offer to buy Avadel Pharmaceuticals , beating a rival bid from Denmark's Lundbeck and valuing the sleep disorder drugmaker at up to $2.37 billion.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN , Nov. 19, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced that the companies have reached agreement ...

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014

The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.

A new bidding war could kick off in biotech with Avadel Pharmaceuticals at the center and initial acquirer Alkermes facing off with Lundbeck.

Alkermes said on Friday it is reviewing its options with advisers after Avadel Pharmaceuticals disclosed it had received an unsolicited takeover proposal from Danish pharmaceutical company Lundbeck.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE IRISH TAKEOVER PANEL ...

U.K. DISCLOSURE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1.      KEY INFORMATION (a) Full name of discloser: Avadel Pharmaceuticals plc (b) Owner or controller of interests and short posit...